{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:08:01Z","timestamp":1790424481913,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1023\/a:1014469828729","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T15:35:40Z","timestamp":1041089740000},"page":"13-22","source":"Crossref","is-referenced-by-count":16,"title":["Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice"],"prefix":"10.1007","volume":"20","author":[{"given":"Lisa","family":"Polin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juiwanna","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Paluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiab","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Hazeldine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome P.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"Suppl","key":"390706_CR1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/13880209509067092","volume":"33","author":"T Corbett","year":"1995","unstructured":"Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lowichik N, Biernat L, Foster B, Wozniak A, Lisow L, Valdivieso M, Baker L, Leopold W, Sebolt J, Bissery MC, Mattes K, Dzubow J, Rake J, Perni R, Wentland M, Coughlin S, Shaw JM, Liversidge G, Liversidge E, Bruno J, Sarpotdar P, Moore R, Patterson G: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J of Pharmacognosy (Suppl) 33: 102\u2013122, 1995","journal-title":"Int J of Pharmacognosy"},{"key":"390706_CR2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1006174622061","volume":"16","author":"TH Corbett","year":"1998","unstructured":"Corbett TH, LoRusso P, Demchik L, Simpson C, Pugh S, White K, Kushner J, Polin L, Meyer J, Czarnecki J, Heilbrun L, Horwitz JP, Gross JL, Behrens CH, Harrison BA, McRipley RJ, Trainor G: Preclinical antitumor efficacy of analogs of XK-469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy] propionate. Invest New Drugs 16: 129\u2013139, 1998","journal-title":"Invest New Drugs"},{"key":"390706_CR3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1006206814025","volume":"16","author":"PM LoRusso","year":"1999","unstructured":"LoRusso PM, Parchment R, Demchik L, Knight J, Polin L, Dzubow J, Behrens C, Harrison BA, Trainor G, Corbett TH: Preclinical antitumor activity of XK469 (NSC656889). Invest New Drugs 16: 287\u2013296, 1999","journal-title":"Invest New Drugs"},{"issue":"21","key":"390706_CR4","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1073\/pnas.96.21.12168","volume":"96","author":"H Gao","year":"1999","unstructured":"Gao H, Huang KC, Yamasaki EF, Chan KK, Chohan L, Snapka RM: XK469, a selective topoisomerase II beta poison. Proc Nat Acad Sci USA 96(21): 12168\u201312173, 1999","journal-title":"Proc Nat Acad Sci USA"},{"key":"390706_CR5","first-page":"1459","volume":"63","author":"FM Schabel Jr","year":"1979","unstructured":"Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr: Cis-dichlorodiammineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459\u20131473, 1979","journal-title":"Cancer Treat Rep"},{"key":"390706_CR6","first-page":"905","volume":"67","author":"FM Schabel Jr","year":"1983","unstructured":"Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH: Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905\u2013922, 1983","journal-title":"Cancer Treat Rep"},{"key":"390706_CR7","first-page":"233","volume-title":"Rodent Tumor Models in Experimental Cancer Therapy","author":"TH Corbett","year":"1987","unstructured":"Corbett TH, Valeriote FA: Rodent models in experimental chemotherapy. In: Kallman RF (ed) Rodent Tumor Models in Experimental Cancer Therapy. Pergamon Press, New York, 1987, Chap 50, pp 233\u2013247"},{"key":"390706_CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00178190","volume":"7","author":"TH Corbett","year":"1989","unstructured":"Corbett TH, Bissery MC, LoRusso PM, Polin L: 5-Fluorouracil containing combinations in murine tumor systems. Invest New Drugs 7: 37\u201349, 1989","journal-title":"Invest New Drugs"},{"issue":"1","key":"390706_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00217664","volume":"5","author":"TH Corbett","year":"1987","unstructured":"Corbett TH, Valeriote FA, Baker LH: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs, 5(1): 3\u201320, 1987","journal-title":"Invest New Drugs"},{"key":"390706_CR10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4615-8152-9_5","volume-title":"Anticancer Drugs Development Guide: Preclinical Screening, Clinical Trials, and Approval","author":"T Corbett","year":"1997","unstructured":"Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lisow L: In vivo methods for screening and preclinical testing; Use of rodent solid tumors for drug discovery. In: Teicher B (ed) Anticancer Drugs Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press Inc, Totowa, New Jersey, 1997, Chap 5, pp 75\u201399, 1997"},{"key":"390706_CR11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1005856605726","volume":"15","author":"L Polin","year":"1997","unstructured":"Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Shaw M, Golakoti T, Patterson G, Moore R, Corbett TH: Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in scid mice. Invest New Drugs 15: 99\u2013108, 1997","journal-title":"Invest New Drugs"},{"key":"390706_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1006267517726","volume":"17","author":"TH Corbett","year":"1999","unstructured":"Corbett TH, Panchapor C, Polin L, Lowichik N, Pugh S, White K, Kushner J, Meyer J, Czarnecki J, Chinnukroh S, Edelstein M, LoRusso P, Horwitz JP, Grieshaber C, Perni R, Wentland M, Coughlin S, Elenbaas S, Philion R, Rake J: Preclinical efficacy of thioxanthone SR-271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs 17: 17\u201327, 1999","journal-title":"Invest New Drugs"},{"key":"390706_CR13","unstructured":"Tosca PJ, Turner NA, Hassler CR, Ryan MJ, Yarrington J, Bollinger LH, Long HA, Schweikart KM, Tomaszewski JE: Toxicity of R(+) XK469 (NSC-698215) and S(-) XK469 (NSC-698216) in rodents and beagle dogs. American Association of Cancer Research 91st Annual Meeting, San Francisco, CA, April 1\u20135, 2000, Proc AACR 41: Abst: 4480, 2000, p705"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1014469828729.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1014469828729\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1014469828729.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:59:24Z","timestamp":1753819164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1014469828729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["390706"],"URL":"https:\/\/doi.org\/10.1023\/a:1014469828729","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}